GlaxoSmithKline has agreed to pay more than $90 million to 38 states as part of settling the claims that the company deliberately misrepresented the health risks associated with diabetes drug Avandia.
A Senate Committee report had earlier found that Avandia increased the risk of cardiovascular disease in diabetic patients and GSK had known about the health risks but had decided not to reveal it.
AdvertisementThe company had been accused of indulging in illegal means to promote the drug and has so far paid more than $3 billion in order to settle federal charges and consumer lawsuits.
P CDC Figures Show Sharp Rise in Number of Diabetes Cases in South of US High Protein Diet May Hasten Wound Healing in Diabetes M
You May Also Like